RxDoctor Payments DataLook up a doctor →

Frederick Min, MD

Hematology & Oncology · Silver Spring, MDNPI 1366682429

Payments from drug & device makers

$1,151,739in general payments, 2019–2025

Across 549 payments — averaging $2097.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$405K
  • Daiichi Sankyo Inc.$176K
  • Novartis$170K
  • Astrazeneca UK Limited$123K
  • Genentech, Inc.$119K
  • Seagen Inc.$81K
  • plus $79K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)28$404,563
Daiichi Sankyo Inc.26$176,223
Novartis44$169,911
Astrazeneca UK Limited8$122,757
Genentech, Inc.14$118,535
Seagen Inc.56$80,599
Hexal AG15$33,340
Pfizer35$28,561
Genmab U.S., Inc.6$5,171
Eisai Inc.7$2,416
Acerta Pharma LLC1$1,125
Rigel Pharmaceuticals, Inc.6$1,108
Johnson & Johnson(2 entities)36$834
Incyte Corporation17$497
Merck21$454
GSK12$290
Bayer10$288
Amgen9$274
Sanofi10$236
Takeda Pharmaceuticals U.S.A., Inc.9$213
AVEO Pharmaceuticals, Inc.7$202
AbbVie7$200
Ipsen Biopharmaceuticals, Inc9$194
Lilly USA, LLC9$179
Mirati Therapeutics, Inc.5$178
Genentech USA, Inc.8$174
Bristol Myers Squibb7$168
Pharmaessentia USA Corporation7$167
Gilead4$150
Regeneron Healthcare Solutions, Inc.7$143
Sobi, Inc7$138
Dexcom, Inc.1$134
Array Biopharma Inc7$117
Pharmacyclics LLC, An Abbvie Company4$114
Beigene USA, Inc.4$111
Puma Biotechnology, Inc.6$107
ADC Therapeutics America, Inc.4$105
Exelixis Inc.4$103
Agios Pharmaceuticals, Inc.4$94
Adaptive Biotechnologies Corporation4$91
Boston Scientific1$87
EMD Serono, Inc.4$86
Tersera Therapeutics LLC3$85
Boehringer Ingelheim3$75
Beone Medicines USA, Inc.3$75
Tactile Systems Technology Inc5$75
Global Blood Therapeutics, Inc.3$74
Dendreon Pharmaceuticals LLC3$67
Kyowa Kirin, Inc.3$66
Stemline Therapeutics Inc.3$59
Astellas Pharma US Inc2$51
Fresenius Kabi USA, LLC2$50
Pharmacosmos Therapeutics Inc.2$50
Deciphera Pharmaceuticals Inc.3$49
Morphosys, US Inc.2$45
Taiho Oncology, Inc.2$43
E.r. Squibb & Sons, L.L.C.2$37
Legend Biotech USA Inc.1$33
Sumitomo Pharma America, Inc.2$32
Menarini Silicon Biosystems, Inc.1$32

How this compares

$1,151,739 in reported general payments places this provider in the 85th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland →

Medicare billing

Part B allowed, 2024
$7,206,943
Medicare patients
735
Services billed
324,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Silver Spring

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →